A citation-based method for searching scientific literature

Gregor Poglajen, Ajda Anžič-Drofenik, Gregor Zemljič, Sabina Frljak, Andraž Cerar, Renata Okrajšek, Miran Šebeštjen, Bojan Vrtovec. Diagnostics (Basel) 2020
Times Cited: 3







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Angiotensin-neprilysin inhibition versus enalapril in heart failure.
John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg,[...]. N Engl J Med 2014
66

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Eric J Velazquez, David A Morrow, Adam D DeVore, Carol I Duffy, Andrew P Ambrosy, Kevin McCague, Ricardo Rocha, Eugene Braunwald. N Engl J Med 2019
530
66


Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
Lourdes Vicent, Alberto Esteban-Fernández, Manuel Gómez-Bueno, Javier De-Juan, Pablo Díez-Villanueva, Ángel Manuel Iniesta, Ana Ayesta, Hugo González-Saldívar, Antonio Rojas-González, Ramón Bover-Freire,[...]. J Cardiovasc Pharmacol 2019
17
33

Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
Herminio Morillas-Climent, Julia Seller-Moya, Álvaro Vicedo-López, Emilio Galcerá-Jornet, Edgard Alania-Torres, Ydelise Rodríguez-Pichardo, Ainhoa Larumbe-Rodríguez, Alfonso Valle-Muñoz. J Comp Eff Res 2019
10
33

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Richard Haynes, Parminder K Judge, Natalie Staplin, William G Herrington, Benjamin C Storey, Angelyn Bethel, Louise Bowman, Nigel Brunskill, Paul Cockwell, Michael Hill,[...]. Circulation 2018
91
33

Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
Antoni Bayes-Genis, Nuria Morant-Talamante, Josep Lupón. Curr Heart Fail Rep 2016
18
33




Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Jessie Gu, Adele Noe, Priya Chandra, Suliman Al-Fayoumi, Monica Ligueros-Saylan, Ramesh Sarangapani, Suzanne Maahs, Gary Ksander, Dean F Rigel, Arco Y Jeng,[...]. J Clin Pharmacol 2010
354
33

Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view.
Borja Quiroga, Antonio de Santos, David Sapiencia, Yamila Saharaui, Vicente Álvarez-Chiva. Nefrologia (Engl Ed) 2019
9
33

Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients.
Gerald Vervoort, Jack F Wetzels, Jos A Lutterman, Bert Bravenboer, Jo H Berden, Paul Smits. Am J Kidney Dis 2002
18
33


Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
David Moher, Larissa Shamseer, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. Syst Rev 2015
33

Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Scott A Hubers, Nancy J Brown. Circulation 2016
116
33

Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.
Jozine M Ter Maaten, Kevin Damman, Marianne C Verhaar, Walter J Paulus, Dirk J Duncker, Caroline Cheng, Loek van Heerebeek, Hans L Hillege, Carolyn S P Lam, Gerjan Navis,[...]. Eur J Heart Fail 2016
182
33

LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.
Wanghui Jing, Nosratola D Vaziri, Ane Nunes, Yasunori Suematsu, Ted Farzaneh, Mahyar Khazaeli, Hamid Moradi. Am J Transl Res 2017
56
33


Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
Kevin Damman, Mauro Gori, Brian Claggett, Pardeep S Jhund, Michele Senni, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Karl Swedberg,[...]. JACC Heart Fail 2018
169
33

Increased capillary hydraulic conductivity induced by atrial natriuretic peptide.
V H Huxley, V L Tucker, K M Verburg, R H Freeman. Circ Res 1987
167
33

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Ramesh R Dargad, Mahesh R Prajapati, Rohit R Dargad, Jai D Parekh. Indian Heart J 2018
12
33

Hyperkalemia in Heart Failure.
Chaudhry M S Sarwar, Lampros Papadimitriou, Bertram Pitt, Ileana Piña, Faiez Zannad, Stefan D Anker, Mihai Gheorghiade, Javed Butler. J Am Coll Cardiol 2016
64
33

Neprilysin inhibition in chronic kidney disease.
Parminder Judge, Richard Haynes, Martin J Landray, Colin Baigent. Nephrol Dial Transplant 2015
68
33

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions.
Lincoln R Potter, Sarah Abbey-Hosch, Deborah M Dickey. Endocr Rev 2006
700
33

Prevention against renal damage in rats with subtotal nephrectomy by sacubitril/valsartan (LCZ696), a dual-acting angiotensin receptor-neprilysin inhibitor.
Kentaro Ushijima, Hitoshi Ando, Yusuke Arakawa, Kenichi Aizawa, Chisato Suzuki, Ken Shimada, Shu-Ichi Tsuruoka, Akio Fujimura. Pharmacol Res Perspect 2017
26
33

Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.
Francesco Spannella, Marco Marini, Federico Giulietti, Giulia Rosettani, Matteo Francioni, Gian Piero Perna, Riccardo Sarzani. Intern Emerg Med 2019
31
33

Hypertensive heart disease and obesity: a complex interaction between hemodynamic and not hemodynamic factors.
Riccardo Sarzani, Marica Bordicchia, Francesco Spannella, Paolo Dessì-Fulgheri, Massimiliano Fedecostante. High Blood Press Cardiovasc Prev 2014
19
33

Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets.
Jens van de Wouw, Michelle Broekhuizen, Oana Sorop, Jaap A Joles, Marianne C Verhaar, Dirk J Duncker, A H Jan Danser, Daphne Merkus. Front Physiol 2019
25
33

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Javad Habibi, Annayya R Aroor, Nitin A Das, Camila M Manrique-Acevedo, Megan S Johnson, Melvin R Hayden, Ravi Nistala, Charles Wiedmeyer, Bysani Chandrasekar, Vincent G DeMarco. Cardiovasc Diabetol 2019
27
33

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Hans L Hillege, Dorothea Nitsch, Marc A Pfeffer, Karl Swedberg, John J V McMurray, Salim Yusuf, Christopher B Granger, Eric L Michelson, Jan Ostergren, Jan Hein Cornel,[...]. Circulation 2006
671
33

Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.
Stefano Bianchi, Filippo Aucella, Luca De Nicola, Simonetta Genovesi, Ernesto Paoletti, Giuseppe Regolisti. J Nephrol 2019
38
33

Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals.
Linda F Fried, Michael G Shlipak, Casey Crump, Anthony J Bleyer, John S Gottdiener, Richard A Kronmal, Lewis H Kuller, Anne B Newman. J Am Coll Cardiol 2003
402
33

Effect of atrial natriuretic factor on the water permeability of endothelial cells.
T Battle, J B Michel, B Corman. Biochem Biophys Res Commun 1992
6
33

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
Po-Cheng Chang, Chun-Li Wang, Fu-Chih Hsiao, Ming-Shien Wen, Chien-Ying Huang, Chung-Chuan Chou, Pao-Hsien Chu. ESC Heart Fail 2020
10
33


Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
Iris E Beldhuis, Koen W Streng, Jozine M Ter Maaten, Adriaan A Voors, Peter van der Meer, Patrick Rossignol, John J V McMurray, Kevin Damman. Circ Heart Fail 2017
67
33

Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Massimo Mapelli, Elisabetta Salvioni, Fabiana de Martino, Irene Mattavelli, Alice Bonomi, Valentina Sassi, Paola Gugliandolo, Carlo Vignati, Alessandra Magini, Sara Rovai,[...]. J Cardiovasc Med (Hagerstown) 2020
6
33

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Scott D Solomon, John J V McMurray, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske,[...]. N Engl J Med 2019
898
33

Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Eugenio Roberto Cosentino, Daniela Degli Esposti, Rinaldo Miceli, Crescenzio Bentivenga, Matteo Landolfo, Arrigo Fg Cicero, Emanuela Berardi, Luca Spinardi, Gianluigi Magri, Vittorio Dugato,[...]. Curr Med Res Opin 2019
13
33

Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Fu-Chih Hsiao, Chun-Li Wang, Po-Cheng Chang, Yu-Ying Lu, Chien-Ying Huang, Pao-Hsien Chu. J Cardiovasc Pharmacol Ther 2020
15
33

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Akshay S Desai, Scott D Solomon, Amil M Shah, Brian L Claggett, James C Fang, Joseph Izzo, Kevin McCague, Cheryl A Abbas, Ricardo Rocha, Gary F Mitchell. JAMA 2019
152
33

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Adriaan A Voors, Mauro Gori, Licette C Y Liu, Brian Claggett, Michael R Zile, Burkert Pieske, John J V McMurray, Milton Packer, Victor Shi, Martin P Lefkowitz,[...]. Eur J Heart Fail 2015
130
33

Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality.
Julio Núñez, Antoni Bayés-Genís, Faiez Zannad, Patrick Rossignol, Eduardo Núñez, Vicent Bodí, Gema Miñana, Enrique Santas, Francisco J Chorro, Anna Mollar,[...]. Circulation 2018
86
33

Molecular biology of the natriuretic peptide system: implications for physiology and hypertension.
David G Gardner, Songcang Chen, Denis J Glenn, Chris L Grigsby. Hypertension 2007
102
33

Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Orly Vardeny, Ryan Miller, Scott D Solomon. JACC Heart Fail 2014
117
33

Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction.
David Montero, Thomas Haider, Jens Barthelmes, Jens P Goetze, Silviya Cantatore, Isabella Sudano, Frank Ruschitzka, Andreas J Flammer. Physiol Rep 2019
5
33

Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials.
Francesco Spannella, Federico Giulietti, Andrea Filipponi, Riccardo Sarzani. ESC Heart Fail 2020
26
33

Transient and sustained increases in glomerular permeability following ANP infusion in rats.
Josefin Axelsson, Anna Rippe, Bengt Rippe. Am J Physiol Renal Physiol 2011
20
33

Pathophysiology of Heart Failure.
Edit Tanai, Stefan Frantz. Compr Physiol 2015
201
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.